Biosenta Inc (ZRO) AI Stock Analysis

• Market Cap: C$4.23M
• Dividend Yield: N/A
• Average Volume (3M): 3.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): -0.02
• Shares Outstanding: 33,831,387
• 10 Day Avg. Volume: 1,949
• 30 Day Avg. Volume: 3,448
• PEG Ratio: 0.02
• Price to Book (P/B): -0.33
• Price to Sales (P/S): 1878.41
• P/FCF Ratio: -3.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 26 Underperform
• Price Target: ―

Biosenta Inc's overall stock score is significantly impacted by its poor financial performance, with negative margins and high leverage being major concerns. The technical analysis suggests bearish trends, further affecting the score. The negative P/E ratio and lack of dividend yield contribute to an unattractive valuation. The absence of earnings call data or notable corporate events means these factors do not influence the score.

Biosenta Inc Business Overview & Revenue Model

Company Description

Biosenta Inc (ZRO) is a company that operates in the environmental and health sectors, focusing on developing innovative products aimed at improving public health and safety. The company specializes in the production of antimicrobial solutions that are designed to disinfect and sanitize various surfaces, providing effective protection against harmful bacteria, fungi, and viruses. Biosenta's core products are positioned to serve both consumer and industrial markets, offering solutions that are environmentally friendly and safe for use in homes, schools, hospitals, and other public spaces.

How the Company Makes Money

Biosenta Inc makes money primarily through the sale of its antimicrobial products, which are marketed to a wide range of customers, including individual consumers, businesses, and institutions. The company's revenue model is based on direct sales as well as partnerships with distributors and retailers who help extend the reach of Biosenta's product offerings. Key revenue streams include product sales in retail locations, online marketplaces, and through direct corporate partnerships. The company's focus on environmentally friendly and effective antimicrobial solutions positions it to capitalize on growing consumer demand for safer and more sustainable cleaning products. Any significant partnerships or licensing agreements that enhance product distribution or innovation capabilities also contribute to Biosenta's earnings.

Biosenta Inc Financial Statement Overview

Summary

Biosenta Inc is experiencing significant financial challenges, with negative profitability, high leverage, and negative cash flows. The company faces significant operational inefficiencies and financial instability, indicating a need for strategic changes to improve financial health.

Income Statement

The company shows negative gross and net profit margins in the TTM, indicating it is not currently profitable. Revenue growth is low, and operating margins such as EBIT and EBITDA are significantly negative, reflecting operational inefficiencies and high operating costs relative to revenue.

Balance Sheet

The balance sheet reveals high leverage with a negative equity position, indicating financial instability. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio is negative, signaling potential financial distress. ROE is also negative, highlighting the lack of returns to shareholders.

Cash Flow

The cash flow statement shows negative operating and free cash flows, indicating the company is not generating enough cash to cover its operations. However, some improvement in free cash flow growth is noted over the periods, though it remains negative. The operating cash flow to net income ratio is negative, reflecting poor cash conversion from earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-198.15K	1.38K	1.04K	1.15K	168.10K	1.53K
Gross Profit	-198.88K	835.00	427.00	728.00	99.11K	55.00
EBITDA	-1.32M	-1.09M	-6.24M	-1.24M	-2.03M	0.00
Net Income	-2.58M	-2.23M	-6.30M	-1.46M	-2.05M	-761.91K
Balance Sheet
Total Assets	122.53K	113.54K	107.59K	256.08K	263.66K	108.83K
Cash, Cash Equivalents and Short-Term Investments	4.69K	8.53K	5.88K	27.26K	111.88K	44.31K
Total Debt	6.37M	5.55M	5.62M	94.77K	152.43K	67.45K
Total Liabilities	9.64M	7.99M	7.96M	3.18M	2.86M	1.98M
Stockholders Equity	-9.51M	-7.88M	-7.86M	-2.92M	-2.59M	-1.87M
Cash Flow
Free Cash Flow	-442.32K	-779.35K	-566.35K	-504.43K	-672.29K	-319.73K
Operating Cash Flow	-416.46K	-779.35K	-550.79K	-504.43K	-672.29K	-319.73K
Investing Cash Flow	-25.86K	0.00	-15.56K	0.00	0.00	0.00
Financing Cash Flow	440.71K	781.99K	544.97K	419.81K	739.86K	354.39K

Biosenta Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Neutral. The current price of 0.1 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.13, and below the 200-day MA of 0.15, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.77 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:ZRO.

Biosenta Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BBM	48 Neutral	C$9.90M	―	-125.85%	―	52.39%	5.13%
CGII	40 Underperform	$5.94M	―	―	―	-8.38%	32.72%
LOBE	38 Underperform	C$9.66M	―	-433.25%	―	-100.00%	-8.70%
ZRO	26 Underperform	C$4.23M	―	―	―	―	―